I. Legssyer

Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions.

P. Delrée, K. Zouaoui Boudjeltia, M. Vanhaeverbeek, 2004, Biochemical and biophysical research communications.

Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.

M. Prévost, P. Moreau, K. Boudjeltia, 2007, Journal of Cardiovascular Pharmacology.

Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation.

C. Remacle, P. Delrée, K. Zouaoui Boudjeltia, 2004, Biochemical and biophysical research communications.

Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.

P. Moreau, K. Zouaoui Boudjeltia, P. Van Antwerpen, 2006, European journal of pharmacology.

Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation.

P. Moreau, K. Boudjeltia, P. Van Antwerpen, 2005, Biochemical and biophysical research communications.

High serum galectin‐3 in advanced melanoma: preliminary results

G. Ghanem, A. Awada, K. Boudjeltia, 2006, Clinical and experimental dermatology.

Triggering of inflammatory response by myeloperoxidase-oxidized LDL.

C. Remacle, P. Delrée, K. Boudjeltia, 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification.

M. Prévost, P. Moreau, P. Van Antwerpen, 2008, Bioorganic & medicinal chemistry.